Cetrorelix
Links shared publicly online about this topic
Ob/Gyn News & Articles - MDLinx - Cetrorelix on #MDlinx
mdlinx.com — “Ob/Gyn News & Articles - MDLinx - Cetrorelix on #MDlinx” View full resource at mdlinx.com
Most Recently Shared on September 3, 2010 at 3:18 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Cetrorelix lowers premature luteinization rate in gonadotropin ovulation induction-intrauterine insemination c... http://bit.ly/ap8r4Q #OBG
Aeterna Zentaris announces results from trials of Cetrorelix in benign prostatic hyperplasia
news-medical.net — “AEterna Zentaris Inc. today reported Phase 3 results for its North American efficacy trial Z-033 and the safety trial Z-041 in benign prostatic hyperplasia (BPH), with its lead endocrinology compound for urology, cetrorelix pamoate. As announced on March 6, 2009, sanofi-aventis U.S. LLC entered into an agreement with AEterna Zentaris for the development, registration and marketing of cetrorelix in BPH for the U.S. market.” View full resource at news-medical.net
Most Recently Shared on August 17, 2009 at 2:00 pm By:
News-Medical.Net Health News and Oncology
Oncology News: Aeterna Zentaris announces results from trials of Cetrorelix in benign prostatic hy.. http://bit.ly/14w23q
Æterna Zentaris reports Phase 3 results of its cetrorelix pamoate Z-036 trial for BPH
news-medical.net — “Æterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia (BPH), with cetrorelix pamoate.” View full resource at news-medical.net
Most Recently Shared on December 7, 2009 at 5:50 pm By:
News-Medical.Net Health News and Oncology
Oncology News: Æterna Zentaris reports Phase 3 results of its cetrorelix pamoate Z-036 trial for BPH: Æterna Zent... http://bit.ly/8FCdXU
AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.
news-medical.net — “AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the termination of its agreement with sanofi-aventis U.S. ( SNY) dated March 5, 2009 for the development, commercialization and licensing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market, following the Company's announcement last week of the results for its European Phase 3 study for cetrorelix in BPH.” View full resource at news-medical.net
Most Recently Shared on December 18, 2009 at 5:04 pm By:
News-Medical.Net Health News and Oncology
Oncology News: AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.: AEterna Zentaris I... http://bit.ly/7B7ULc
Phase 3 results for European efficacy trial Z-036 in BPH with cetrorelix pamoate reported
news-medical.net — “AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia (BPH), with cetrorelix pamoate.” View full resource at news-medical.net
Most Recently Shared on December 8, 2009 at 5:12 am By:
News-Medical.Net Health News and Oncology
Oncology News: Phase 3 results for European efficacy trial Z-036 in BPH with cetrorelix pamoate reported: AEterna Z... http://bit.ly/6r8uSK
[Use of GnRh antagonist (Cetrorelix) in controlled... [Tunis Med. 2008] - PubMed result
ncbi.nlm.nih.gov — “PubMed is a service of the U.S. National Library of Medicine that includes over 18 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950s. PubMed includes links to full text articles and other related resources.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on April 2, 2009 at 12:45 am By:
Vel Ravimohan Doctor, ObGyn Physician, Surgeon, and Physician
PCOS news [Use of GnRh antagonist (Cetrorelix) in controlled ovarian hyperstimulation in women with pol.. http://tinyurl.com/d53s2e
Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix - Rozsa - 2010 - The Prostate - Wiley Online Library
onlinelibrary.wiley.com — “Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix - Rozsa - 2010 - The Prostate - Wiley Online Library” View full resource at onlinelibrary.wiley.com
Most Recently Shared on September 23, 2010 at 11:53 am By:
Urology & Nephrology OW Health
Receptors for luteinizing hormoneâ€*releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential mo... http://bit.ly/bz24Ge
Fertility Drug Shows Potential Against Hot Flashes - Drugs.com MedNews
drugs.com — “A powerful fertility drug may have another use for older women stopping hot flashes. In a letter to the editor in the Sept. 17 issue of the New England Journal ” View full resource at drugs.com
Most Recently Shared on September 16, 2009 at 10:55 pm By:
Fertility Drug Shows Potential Against Hot Flashes - http://bit.ly/LTxJw
Fertility Drug Shows Potential Against Hot Flashes
health.msn.com — “Fertility Drug Shows Potential Against Hot Flashes” View full resource at health.msn.com
Most Recently Shared on September 16, 2009 at 9:21 pm By:
Fertility Drug Shows Potential Against Hot Flashes http://bit.ly/2PfyJ
Subscription Center - News Archive
pharmalive.com — “Subscription Center - News Archive” View full resource at pharmalive.com
Most Recently Shared on December 18, 2009 at 8:51 pm By:
PharmaLive Pharma and Health News
Sanofi, Aeterna Zentaris Cetrorelix Pact Ends-http://tinyurl.com/ycmkuxt
Subscription Center - News Archive
pharmalive.com — “Subscription Center - News Archive” View full resource at pharmalive.com
Most Recently Shared on December 8, 2009 at 4:53 pm By:
PharmaLive Pharma and Health News
AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix - http://tinyurl.com/yzu64pe
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
-
News-Medical.Net
Stay up to date with the latest Oncology news and research via News-Medical.Net
-
News-Medical.Net
Stay up to date with the latest Oncology news and research via News-Medical.Net
Advertisement
